Lessons from the African-American study of kidney disease and hypertension: An update

Current Hypertension Reports

Volumn 8, Issue 5, 2006, Pages 409-412

  Toto, Robert D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; RAMIPRIL;

AFRICAN AMERICAN; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME INHIBITION; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPERTENSIVE NEPHROSCLEROSIS; KIDNEY DISEASE; KIDNEY FAILURE; NEPHROSCLEROSIS; PREDICTION; PROTEINURIA; REVIEW; RISK ASSESSMENT; RISK REDUCTION; TREATMENT OUTCOME; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; AFRICAN CONTINENTAL ANCESTRY GROUP; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; METOPROLOL; NEPHROSCLEROSIS; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 33749076916     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0087-7     Document Type: Review

References (17)

1. USRDS: U.S. Renal Data System, USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2002.
2. Collins AJ, Kasiske B, Herzog C, et al.: Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2005, 45:A5-A7.
3. Wright JT, Kusek JW, Toto RD, et al.: Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 1996, 17:3S-16S.
4. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
5. Wright JT Jr, Bakris G, Greene T, et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421-2431.
6. Materson B, Reda DJ, Cushman WC, et al.: Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl Med 1993, 328:914-921.
7. Weir MR, Kong BW, Jenkins P, Lavin PT: Comparison of the efficacy and tolerability of lisinopril and sustained-release verapamil in black patients with hypertension. Clin Ther 1991, 13:409-416.
8. Agodoa LY, Appel L, Bakris GL, et al.: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285:2719-2728.
9. Klahr S, Levey AS, Beck GJ, et al.: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group [see comments]. N Engl J Med 1994, 330:877-894.
10. Jafar TH, Stark PC, Schmid CH, et al.: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001, 60:1131-1140.
11. Jafar TH, Schmid CH, Stark PC, et al.: The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrol Dial Transplant 2003, 18:2047-2053.
12. Keane W, Brenner B, deZeeuw D, et al.: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney Int 2003 63:1499-1507.
13. Contreras G, Greene T, Agodoa LY, et al.: Blood Pressure Control, Drug Therapy, and Kidney Disease. Hypertension 2005, 46:44-50.
14. Lindeman RD, Tobin JD, Shock NW: Association between blood pressure and the rate of decline in renal function with age. Kidney Int 1984, 26:861-868.
15. Lewis EJ, Hunsicker L, Bain R, et al.: The Effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456-1462.
16. Gissen Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997, 349:1857-1863.
17. National Kidney Foundation: KDOQI Clinical Practice Guideline for hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43:1-290.